Bedrijfsoverzicht
Cytosorbents Corporation is engaged in the research, development, and commercialization of specialized medical devices, utilizing a proprietary blood purification technology platform that incorporates specific adsorbent and porous polymer technologies within the United States, Germany, and international markets. This operational focus places the company within the Healthcare sector, specifically the Medical Devices industry, an area characterized by high barriers to entry and significant regulatory scrutiny regarding patient safety and device efficacy. The organization currently employs 129 individuals to support its global operations and product lifecycle management. With a market capitalization of $38.31M and an annual revenue of $37.06M, Cytosorbents operates on a relatively small scale compared to established industry giants. These valuation and revenue figures indicate that the company is a micro-cap entity with limited market penetration, suggesting it is still in a phase where establishing market share and commercializing its technology platform is the primary operational objective rather than maximizing shareholder returns through large-scale volume sales.
Financiële gezondheid
The company reported a revenue of $37.06M over the trailing twelve months, yet recorded a net income of -$8,198,000, revealing a cost structure where expenses significantly outpace gross profitability. This negative net income is further contextualized by an EBITDA of -$12,743,000, indicating that even before interest and tax adjustments, the core business operations are generating a cash shortfall that requires external financing to sustain. The free cash flow stands at -$2,071,875, which signifies a lack of financial flexibility and implies that the company is burning cash and must rely on its existing liquidity or additional capital raises to fund operations and research. Regarding profitability metrics, the gross margin is 71.5%, which suggests a high-margin product offering where the core cost of goods sold is low relative to sales; however, this is contrasted sharply by an operating margin of -43.9% and a profit margin of -22.1%, demonstrating that high fixed costs or significant research and development expenditures are eroding overall profitability. The balance sheet shows a cash position of $6.25M against total debt of $29.11M, resulting in a debt-to-equity ratio of 493.16, which characterizes the company as highly leveraged with a capital structure that exposes it to significant solvency risk if cash flows do not improve. Despite the debt load, the current ratio of 2.12 indicates that the company holds sufficient current assets to cover its short-term liabilities, providing a buffer against immediate liquidity crises. Furthermore, the return on equity is -96.4% and the return on assets is -19.4%, metrics that reveal management has not yet generated positive returns on the capital invested in the business, highlighting the challenges of scaling a pre-commercial or early-stage medical device portfolio.
Waarderingsbeoordeling
The valuation metrics for Cytosorbents Corporation reflect its status as a non-profitable entity, evidenced by a trailing P/E ratio of N/A and a forward P/E of inf, both of which imply that the market cannot value the stock based on current or expected earnings due to the persistent negative income trajectory. The price-to-book ratio stands at 6.49, indicating that the market values the company's equity at a significant premium over its book value, a discrepancy often seen in small-cap biotech or medtech firms where investors price in potential future breakthroughs rather than current assets. Alternative valuation measures such as the price-to-sales ratio of 1.03 and an EV/EBITDA of -4.79 further suggest that the stock is priced based on top-line revenue generation rather than profitability, as the negative EV/EBITDA confirms that enterprise value is heavily influenced by the company's negative earnings and high debt load. The stock's trading range over the past year has seen a 52-week high of $1.39 and a 52-week low of $0.50, providing a historical context for price volatility and investor sentiment swings within the micro-cap healthcare space. The beta of 1.48 indicates that the stock's price volatility is substantially higher than the broader market, meaning that CTSO is expected to experience larger price swings than the overall market index during periods of equity market turbulence.
Growth & Income
Revenue growth for the trailing twelve months was 0.9%, while earnings growth is N/A due to the company's ongoing net losses, implying that the top line is stable but not expanding rapidly enough to offset the high fixed costs associated with R&D and manufacturing. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%, which means that all available cash flow is currently being retained to fund operations and potentially fund future growth initiatives rather than being distributed to shareholders. The absence of a dividend policy is consistent with the company's life-cycle stage, where reinvesting earnings into the proprietary technology platform is a more strategic priority than providing income to investors. In summary, Cytosorbents Corporation presents a growth and income profile characterized by stable but minimal revenue expansion, zero dividend income, and a capital allocation strategy focused entirely on sustaining operations and developing its medical device portfolio rather than delivering financial returns to equity holders.